Chromatin signaling mechanisms in metabolic aging and disease
Active Grant Awarded
- Award ID
- R01AG093112
- Recipient
-
Palo Alto Veterans Institute For Research UEI H58TR2D7DNE3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $542,730
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 9% complete
- Place of performance
- California, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Palo Alto Veterans Institute For Research, doing business as Pavir, $542,730 on June 9, 2026, under the Aging Research program (CFDA 93.866) through grant R01AG093112. The project studies SIRT7, a mammalian sirtuin lysine deacetylase, and its role in histone deacetylation within chromatin regulatory mechanisms that are deregulated in aging-associated metabolic pathologies. Investigators use biochemical, cellular, and genomic approaches with SIRT7 knockout mice and new mouse models that overexpress SIRT7. The central hypothesis is that SIRT7 protects against aging and metabolic disease processes and attenuates metabolic pathologies when overexpressed. The project also hypothesizes that histone H3K36 is a novel SIRT7 substrate that contributes to SIRT7's functions in aging and metabolic pathways. The dollars obligated are $542,730, the ultimate completion date is April 30, 2031, and place of performance is California, USA. The Aging Research program encourages biomedical, social, and behavioral research and research training on the aging process and related diseases, with particular emphasis on preventing and treating Alzheimer's disease and related dementias.
Description
- Abstract
- Our broad research goal is to understand chromatin regulatory mechanisms in nuclear and epigenetic programs and how these mechanisms are deregulated in aging and disease. A fundamental mechanism for regulating chromatin involves the reversible modification of histones by chemical moieties such as acetyl-, methyl-, and phospho- groups. These different histone marks are linked to discrete chromatin states and regulate the accessibility of DNA to transacting factors. In budding yeast, histone deacetylation by the chromatin silencing factor SIR2 prevents genomic instability and aging, and in mammals, DE-regulation of histone acetylation is linked to cellular senescence and aging-related pathologies from neurodegeneration to cancer. Here, we focus on the mammalian SIR2 family member SIRT7, a chromatin regulatory, highly selective, lysine deacetylase enzyme. Previous studies reported that loss of SIRT7 function in mice leads to genomic instability, shortened lifespan and aging-related phenotypes including fatty liver, cardiac disease, and hematopoietic stem cell dysfunction. This project will study new roles of SIRT7-dependent histone deacetylation in chromatin regulatory mechanisms that are deregulated in aging-associated metabolic pathologies. IT employs biochemical, cellular, and genomic approaches, and leverages SIRT7 knockout (SIRT7-KO) mice and new mouse models in which SIRT7 is overexpressed (SIRT7-OE). A central hypothesis is that SIRT7 protects against aging and metabolic disease processes and attenuates metabolic pathologies when overexpressed in mice. The project also hypothesizes that a novel histone substrate of SIRT7, H3K36, contributes to functions of SIRT7 in aging and metabolic pathways. Little is known about acetylation of H3K36, but DI-methylation of H3K36 (a histone modification linked to gene regulation) is implicated in many human cancers, developmental disorders, and recently, metabolic disease. We hypothesize that deacetylation of H3K36 by SIRT7 is coupled to methylation by lysine methyltransferase (KMT) enzymes. We will test the model that a key mechanistic function of SIRT7 is to clear H3K36 acetylation from large swaths of DNA across the genome to enable methylation by kmts, and that such a H3K36 acetyl-methyl switch mechanism is essential for preventing aging-associated gene expression reprograming in metabolic tissues.
Quick answers
Who received award R01AG093112?
R01AG093112 was awarded to Palo Alto Veterans Institute For Research by National Institute on Aging (National Institutes of Health) on June 9, 2026.
How much is award R01AG093112 worth?
$542,730 has been obligated on R01AG093112.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award